Episode Summary
This episode presents an evidence-based analysis of the relationship between acne vulgaris and metabolic dysfunction, with emphasis on insulin resistance, insulin-like growth factor-1 (IGF-1) signaling, and mTORC1 pathway activation. While acne is traditionally attributed to androgen activity and follicular hyperkeratinization, emerging research reveals that systemic metabolic disturbances—particularly insulin resistance and related endocrine pathways—significantly influence disease severity and treatment outcomes. The analysis integrates dermatological and metabolic medicine perspectives to inform clinical decision-making in complex acne cases.
Key Topics Discussed
- Insulin resistance and glucose metabolism in relation to acne severity and persistence
- IGF-1 and mTORC1 signaling pathways as central biological drivers of sebaceous gland dysfunction and inflammation
- Obesity, adipokines, and chronic low-grade inflammation in acne pathogenesis
- Dyslipidemia and its heterogeneous associations with acne vulgaris
- Acne as a manifestation of polycystic ovary syndrome and other endocrine disorders
- Metabolic syndrome components versus unified metabolic syndrome classification in acne etiology
Key Takeaways
- While acne should not be classified as a metabolic disease, its severity is influenced by systemic metabolic and hormonal dysfunction
- Strongest evidence supports insulin resistance and IGF-1–mediated pathways as key biological mechanisms linking metabolism to acne outcomes
- Individual metabolic syndrome components show variable associations with acne, suggesting mechanistic heterogeneity
- Integrated, patient-centered dermatological approaches incorporating metabolic assessment are indicated for severe, persistent, treatment-resistant, and hormonally driven acne
- Early identification of metabolic risk factors and interdisciplinary care between dermatology and internal medicine improve clinical outcomes
About This Episode
Acne vulgaris affects millions globally and represents a significant public health concern. Understanding the metabolic dimensions of acne pathogenesis has important implications for clinical practice, particularly in cases refractory to conventional dermatological treatment. This episode supports evidence-based integration of metabolic and hormonal evaluation into comprehensive acne management protocols, with relevance to clinicians across dermatology, endocrinology, and primary care settings. The research underscores the necessity for further investigation clarifying causality and guiding targeted interventions in metabolic-phenotype acne cases.
Acne vulgaris is one of the most common dermatological conditions worldwide, traditionally explained by androgen activity, follicular hyperkeratinization, sebaceous gland dysfunction, microbial imbalance, and inflammation. However, growing evidence indicates that systemic metabolic disturbances — particularly insulin resistance and related endocrine pathways — may play a significant role in disease severity and persistence.
This episode explores how metabolic mechanisms influence dermatological outcomes, highlighting the role of insulin signaling, insulin-like growth factor-1 (IGF-1), and mTORC1 pathways in promoting sebaceous gland activity, inflammation, and increased androgen bioavailability.
The episode examines key clinical and public health considerations, including:
• The role of insulin resistance and glucose metabolism in acne severity
• IGF-1 and mTORC1 signaling as central biological drivers
• The influence of obesity, adipokines, and chronic low-grade inflammation
• Dyslipidemia and its heterogeneous association with acne
• Links between acne and endocrine disorders such as polycystic ovary syndrome
• The distinction between metabolic syndrome and its individual components
The findings suggest that while acne should not be classified as a metabolic disease, its severity may be influenced by systemic metabolic and hormonal processes. The strongest evidence supports a role for insulin resistance and IGF-1–mediated pathways, while associations with metabolic syndrome as a unified condition remain inconsistent.
From a clinical perspective, this episode supports a more integrated, patient-centered dermatological approach, particularly in cases of severe, persistent, treatment-resistant, or hormonally driven acne.
This episode highlights the importance of interdisciplinary care, early identification of metabolic risk factors, and the need for further research to clarify causality and guide targeted interventions.
https://doi.org/10.5281/zenodo.19135373
Citation:Inaishvili, M., & Glonti, S. (2026). Metabolic Dysfunction and Acne Severity: Mechanisms and Clinical Implications. The Georgian Medical Journal.
https://doi.org/10.5281/zenodo.19135373